Proteomic identification of predictive biomarkers of neo-adjuvant chemotherapy resistance in breast cancer: A possible role of AkT-1, FAKY397, 14-3-3 theta/tau, tBID and BcL-XL?

Abstract

Background: Neoadjuvant chemotherapy is a standard treatment for locally advanced breast cancer. However, chemoresistance can be a major obstacle in ER+ cancers. Using comparative proteomic approaches (antibody microarray/AbMA and 2D-PAGE with MALDI-TOF/TOF MS) to investigate a pilot series of breast cancer samples we recently identified 14-3-3 theta/tau, tBID and BcL-XL as putative biomarkers of response to neoadjuvant chemotherapy (Hodgkinson et al J Prot 2012, 75:1276–1283 and 75:2745–2752). Here we aimed to analyse further samples using the AbMA approach and to re-analyse the combined data.